Healthnostics re-designs its Biomedicine web portal

NewsGuard 100/100 Score

Healthnostics, Inc. (OTC PK: HNSS), a medical and biotechnology analytics company today delineated its strategy for the biomedical content layer of the re-design of its Biomedicine Web Portal, MedBioWorld.com.

A major shift in strategy by MedBioWorld.com will consist of broadening the access to its content from a strictly professional base to a wider, more general audience. This will be accomplished by enhancing the portal's database navigation engine currently indexed using the National Library of Medicine's Medical Subject Headings (MeSH) controlled vocabulary. The engine will be augmented by a new index consisting of Consumer Health Topics.

This approach will allow the company to broaden the scope of its content while preserving MedBioWorld's rich professional biomedical content for its loyal professional customer base. In addition the consumer content will be supplemented with Expert Commentary and the user experience will be enhanced by Web 2.0 interactive features.

"We will offer consumers the full spectrum of biomedical resources relevant to their topic of interest. Standard consumer level medical information is widely available on the internet, and we feel consumers should be given the opportunity to dig deeper should they decide to," said Alan Grofe, president. "Our biomedical content strategy aims at facilitating that process by providing them with a one-stop gateway to comprehensive coverage of consumer medical topics."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study to test novel psychedelic compound as potential treatment for alcohol use disorder